AU2017275782B2 - A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer - Google Patents

A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Download PDF

Info

Publication number
AU2017275782B2
AU2017275782B2 AU2017275782A AU2017275782A AU2017275782B2 AU 2017275782 B2 AU2017275782 B2 AU 2017275782B2 AU 2017275782 A AU2017275782 A AU 2017275782A AU 2017275782 A AU2017275782 A AU 2017275782A AU 2017275782 B2 AU2017275782 B2 AU 2017275782B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
sequence
cancer
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017275782A
Other languages
English (en)
Other versions
AU2017275782A1 (en
Inventor
Gustav Gaudernack
Audun Tornes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultimovacs ASA
Original Assignee
Ultimovacs ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimovacs ASA filed Critical Ultimovacs ASA
Publication of AU2017275782A1 publication Critical patent/AU2017275782A1/en
Application granted granted Critical
Publication of AU2017275782B2 publication Critical patent/AU2017275782B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2017275782A 2016-06-02 2017-06-02 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Ceased AU2017275782B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16172760 2016-06-02
EP16172760.7 2016-06-02
PCT/EP2017/063589 WO2017207814A1 (en) 2016-06-02 2017-06-02 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Publications (2)

Publication Number Publication Date
AU2017275782A1 AU2017275782A1 (en) 2019-01-24
AU2017275782B2 true AU2017275782B2 (en) 2024-08-15

Family

ID=56132759

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017275782A Ceased AU2017275782B2 (en) 2016-06-02 2017-06-02 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Country Status (17)

Country Link
US (2) US11419927B2 (https=)
EP (2) EP4253419A3 (https=)
JP (2) JP7321709B2 (https=)
AU (1) AU2017275782B2 (https=)
CA (1) CA3026172A1 (https=)
CY (1) CY1126489T1 (https=)
DK (1) DK3463436T3 (https=)
ES (1) ES2965957T3 (https=)
FI (1) FI3463436T3 (https=)
HR (1) HRP20231650T1 (https=)
HU (1) HUE065176T2 (https=)
LT (1) LT3463436T (https=)
PL (1) PL3463436T3 (https=)
PT (1) PT3463436T (https=)
RS (1) RS65007B1 (https=)
SI (1) SI3463436T1 (https=)
WO (1) WO2017207814A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2536830T3 (pl) 2010-02-16 2020-02-28 Ultimovacs As Polipeptydy
EP4253419A3 (en) 2016-06-02 2024-05-22 Ultimovacs ASA A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
GB201803178D0 (en) * 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
TWI805792B (zh) * 2018-06-29 2023-06-21 日商大鵬藥品工業股份有限公司 抗腫瘤劑及其評估方法
US20250152688A1 (en) 2021-06-09 2025-05-15 Ultimovacs Ab A Conjugate
WO2024083866A1 (en) 2022-10-17 2024-04-25 Ultimovacs Asa Cancer treatment
WO2024126758A2 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide
WO2024126737A1 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A core and a conjugate

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2536830T3 (pl) 2010-02-16 2020-02-28 Ultimovacs As Polipeptydy
LT2547364T (lt) 2010-03-15 2017-03-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptidai, konjugatai ir vakcinos imunogeniškumo padidinimo būdas
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
US9561266B2 (en) 2012-08-31 2017-02-07 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
US9974845B2 (en) * 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
KR20150130284A (ko) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
US20170035864A1 (en) 2013-12-09 2017-02-09 Bullet Biotechnology, Inc. SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015096811A1 (zh) 2013-12-27 2015-07-02 厦门松霖科技有限公司 暗装预埋组件
ES2738582T3 (es) 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
WO2015128313A1 (en) 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
KR102499737B1 (ko) 2014-05-13 2023-02-13 버베리안 노딕 에이/에스 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
US20170136127A1 (en) 2014-07-01 2017-05-18 Vicus Therapeutics, Llc Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
EP3166646A4 (en) 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
EP3169355A4 (en) 2014-07-18 2018-07-25 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016063263A2 (en) 2014-10-23 2016-04-28 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
US11236139B2 (en) 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
MX2018008797A (es) 2016-01-19 2018-11-29 Pfizer Vacunas contra el cancer.
EP4253419A3 (en) 2016-06-02 2024-05-22 Ultimovacs ASA A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies

Also Published As

Publication number Publication date
PT3463436T (pt) 2023-12-28
CA3026172A1 (en) 2017-12-07
US12168045B2 (en) 2024-12-17
DK3463436T3 (da) 2023-12-18
JP7321709B2 (ja) 2023-08-07
EP4253419A2 (en) 2023-10-04
EP3463436B1 (en) 2023-09-20
CY1126489T1 (el) 2026-02-25
LT3463436T (lt) 2024-01-25
HRP20231650T1 (hr) 2024-05-10
US11419927B2 (en) 2022-08-23
RS65007B1 (sr) 2024-01-31
EP4253419A3 (en) 2024-05-22
EP3463436A1 (en) 2019-04-10
HUE065176T2 (hu) 2024-05-28
US20230049012A1 (en) 2023-02-16
US20190247482A1 (en) 2019-08-15
JP2019517508A (ja) 2019-06-24
SI3463436T1 (sl) 2024-02-29
FI3463436T3 (fi) 2023-12-04
ES2965957T3 (es) 2024-04-17
WO2017207814A1 (en) 2017-12-07
PL3463436T3 (pl) 2024-03-04
AU2017275782A1 (en) 2019-01-24
JP2022171684A (ja) 2022-11-11

Similar Documents

Publication Publication Date Title
US12168045B2 (en) Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
US20230277641A1 (en) Telomerase polypeptide vaccine for treating cancer
US20230414735A1 (en) Neoantigens and methods of their use
KR102823333B1 (ko) 암 치료 방법 및 조성물
CN111093691A (zh) 蛋白质抗原及其用途
TR201900852T4 (tr) Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşı yeni immünoterapi.
RS53872B1 (sr) Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
TW201106962A (en) CDC45L peptides and vaccines including the same
US20060045884A1 (en) Vaccines for autoimmune and infectious disease
WO2024083866A1 (en) Cancer treatment
Thomas Development of a prostatic acid phosphatase-derived vaccine for the treatment of advanced prostate cancer
HK40113603A (zh) 蛋白质抗原及其用途
KR20220010712A (ko) Wt1-양성 암을 치료하기 위한 다가 면역요법 조성물 및 사용 방법
HK40029579A (en) Protein antigens and uses thereof
Javad Development of prostrate cancer vaccine using PAP as target antigen
HK1177762A (en) Polypeptides
HK1177762B (en) Polypeptides
HK40004257A (en) Neoantigens and methods of their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired